# Evaluation of Lippia scaberrima Sond. and Aspalathus linearis (Burm.f.) R. Dahlgren extracts on human CYP enzymes and gold nanoparticle synthesis: implications for drug metabolism and cytotoxicity

**Authors:** Anna-Mari Kok, Risto Juvonen, Markku Pasanen, Vusani Mandiwana, Michel Lonji Kalombo, Suprakas Sinha Ray, Rirhandzu Rikhotso-Mbungela, Namrita Lall

PMC · DOI: 10.1186/s12906-024-04439-9 · BMC Complementary Medicine and Therapies · 2024-04-05

## TL;DR

This study evaluates how plant extracts affect liver enzymes and creates gold nanoparticles with reduced toxicity.

## Contribution

The study introduces a new evaluation of plant extract effects on CYP enzymes and demonstrates gold nanoparticle synthesis with reduced cytotoxicity.

## Key findings

- Lippia scaberrima essential oil and extracts showed potent inhibition of CYP2C19 and CYP1B1 enzymes.
- Gold nanoparticles synthesized from Lippia scaberrima showed twofold reduced cytotoxicity compared to the extract.
- Most CYP enzyme inhibition levels were not clinically significant, suggesting potential for use in drug regimens.

## Abstract

Metabolism is an important component of the kinetic characteristics of herbal constituents, and it often determines the internal dose and concentration of these effective constituents at the target site. The metabolic profile of plant extracts and pure compounds need to be determined for any possible herb-drug metabolic interactions that might occur.

Various concentrations of the essential oil of Lippia scaberrima, the ethanolic extract of Lippia scaberrima alone and their combinations with fermented and unfermented Aspalathus linearis extract were used to determine the inhibitory potential on placental, microsomal and recombinant human hepatic Cytochrome P450 enzymes. Furthermore, the study investigated the synthesis and characterization of gold nanoparticles from the ethanolic extract of Lippia scaberrima as a lead sample. Confirmation and characterization of the synthesized gold nanoparticles were conducted through various methods. Additionally, the cytotoxic properties of the ethanolic extract of Lippia scaberrima were compared with the gold nanoparticles synthesized from Lippia scaberrima using gum arabic as a capping agent.

All the samples showed varying levels of CYP inhibition. The most potent inhibition took place for CYP2C19 and CYP1B1 with 50% inhibitory concentration (IC50) values of less than 0.05 µg/L for the essential oil tested and IC50-values between 0.05 µg/L-1 µg/L for all the other combinations and extracts tested, respectively. For both CYP1A2 and CYP2D6 the IC50-values for the essential oil, the extracts and combinations were found in the range of 1 – 10 µg/L. The majority of the IC50 values found were higher than 10 µg/L and, therefore, were found to have no inhibition against the CYP enzymes tested.

Therefore, the essential oil of Lippia scaberrima, the ethanolic extract of Lippia scaberrima alone and their combinations with Aspalathus linearis do not possess any clinically significant CYP interaction potential and may be further investigated for their adjuvant potential for use in the tuberculosis treatment regimen. Furthermore, it was shown that the cytotoxic potential of the Lippia scaberrima gold nanoparticles was reduced by twofold when compared to the ethanolic extract of Lippia scaberrima.

The online version contains supplementary material available at 10.1186/s12906-024-04439-9.

## Linked entities

- **Proteins:** CYP2C19 (cytochrome P450 family 2 subfamily C member 19), CYP1B1 (cytochrome P450 family 1 subfamily B member 1), CYP1A2 (cytochrome P450 family 1 subfamily A member 2), CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene))
- **Species:** Aspalathus linearis (taxon 155124)

## Full-text entities

- **Genes:** CYP2C19 (cytochrome P450 family 2 subfamily C member 19) [NCBI Gene 1557] {aka CPCJ, CYP2C, CYPIIC17, CYPIIC19, P450C2C, P450IIC19}, CYP4F3 (cytochrome P450 family 4 subfamily F member 3) [NCBI Gene 4051] {aka CPF3, CYP4F, CYPIVF3, LTB4H}, CYP1A2 (cytochrome P450 family 1 subfamily A member 2) [NCBI Gene 1544] {aka CP12, CYPIA2, P3-450, P450(PA)}, CYP1B1 (cytochrome P450 family 1 subfamily B member 1) [NCBI Gene 1545] {aka ASGD6, CP1B, CYPIB1, GLC3A, P4501B1}, CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)) [NCBI Gene 1565] {aka CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2}
- **Diseases:** cytotoxic (MESH:D064420), tuberculosis (MESH:D014376)
- **Species:** Homo sapiens (human, species) [taxon 9606], Aspalathus linearis (rooibos, species) [taxon 155124]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10996199/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10996199/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC10996199/full.md

---
Source: https://tomesphere.com/paper/PMC10996199